S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:KRON

Kronos Bio (KRON) Stock Price, News & Analysis

$1.30
+0.06 (+4.84%)
(As of 03/28/2024 ET)
Today's Range
$1.22
$1.35
50-Day Range
$1.02
$1.30
52-Week Range
$0.73
$2.29
Volume
309,231 shs
Average Volume
523,595 shs
Market Capitalization
$78.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.25

Kronos Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
226.9% Upside
$4.25 Price Target
Short Interest
Healthy
1.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Kronos Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$43,197 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.81) to ($1.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.47 out of 5 stars

Medical Sector

340th out of 938 stocks

Pharmaceutical Preparations Industry

148th out of 417 stocks

KRON stock logo

About Kronos Bio Stock (NASDAQ:KRON)

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.

KRON Stock Price History

KRON Stock News Headlines

Recap: Kronos Bio Q4 Earnings
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Kronos Bio reports Q4 results
KRON Kronos Bio, Inc.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Kronos Bio to Cut About 21% of Workforce
Kronos Bio, Inc. (KRON)
KRON Mar 2024 2.500 put
Kronos Bio Inc
See More Headlines
Receive KRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KRON
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.25
High Stock Price Target
$6.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+226.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-112,670,000.00
Net Margins
-1,791.87%
Pretax Margin
-1,791.87%

Debt

Sales & Book Value

Annual Sales
$6.29 million
Book Value
$2.73 per share

Miscellaneous

Free Float
46,033,000
Market Cap
$78.13 million
Optionable
Optionable
Beta
1.77
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Norbert W. Bischofberger Ph.D.Dr. Norbert W. Bischofberger Ph.D. (Age 68)
    President, CEO & Director
    Comp: $809.7k
  • Mr. Joshua A. Kazam (Age 47)
    Co-Founder & Director
    Comp: $40k
  • Ms. Sandra A. Gardiner (Age 58)
    Interim CFO & Principal Accounting Officer
  • Dr. Elizabeth A. Olek D.O. (Age 59)
    M.P.H., Senior Vice President of Clinical Development
  • Mr. Wes Trotter Ph.D.
    Senior Vice President of Drug Discovery & Pharmaceutical Development
  • Ms. Rocio Martin Hoyos
    Senior Vice President of Corporate Strategy & Portfolio Management

KRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Kronos Bio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRON shares.
View KRON analyst ratings
or view top-rated stocks.

What is Kronos Bio's stock price target for 2024?

2 analysts have issued 12-month price objectives for Kronos Bio's shares. Their KRON share price targets range from $2.50 to $6.00. On average, they expect the company's stock price to reach $4.25 in the next year. This suggests a possible upside of 226.9% from the stock's current price.
View analysts price targets for KRON
or view top-rated stocks among Wall Street analysts.

How have KRON shares performed in 2024?

Kronos Bio's stock was trading at $1.25 at the start of the year. Since then, KRON shares have increased by 4.0% and is now trading at $1.30.
View the best growth stocks for 2024 here
.

When is Kronos Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our KRON earnings forecast
.

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.40. Kronos Bio had a negative trailing twelve-month return on equity of 58.79% and a negative net margin of 1,791.87%.

When did Kronos Bio IPO?

Kronos Bio (KRON) raised $175 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

Who are Kronos Bio's major shareholders?

Kronos Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.92%), Vanguard Group Inc. (2.92%), Cerity Partners LLC (0.70%), Bridgeway Capital Management LLC (0.50%), Citadel Advisors LLC (0.34%) and GSA Capital Partners LLP (0.04%). Insiders that own company stock include Backer Marianne De, Barbara Kosacz, Christopher Dinsmore, Elizabeth A Olek, Jakob Loven, Jorge Dimartino, Norbert W Bischofberger and Yasir B Al-Wakeel.
View institutional ownership trends
.

How do I buy shares of Kronos Bio?

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRON) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners